佛塑科技(000973.SZ)一季度淨利潤預降10.98%-33.24%
格隆匯4月13日丨佛塑科技(000973.SZ)公佈,預計2020年第一季度歸屬於上市公司股東的淨利潤750萬元–1000萬元,同比下降10.98%-33.24%。
隨着新型冠狀病毒肺炎疫情蔓延,國內外經濟形勢發生重大變化,面對複雜多變的國內外經濟環境,公司上下齊心協力,攻堅克難,積極應對外部環境的挑戰,堅持防控疫情與生產經營兩手抓、兩手硬、兩不誤,視情況適時調整生產經營策略,切實履行社會責任,努力提供防疫物資保障,但受上下游復工復產延遲、人工短缺、物流配送滯後、部分產品市場需求減少等不利因素影響,2020年第一季度歸屬於上市公司股東的淨利潤比2019年同期有所下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.